GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
GenMark Diagnostics, Inc. (“GenMark”) held its 2018 Annual Meeting of Stockholders on May24, 2018 (the “Annual Meeting”), at which a total of 51,559,705 shares of GenMark common stock, or approximately 93% of the shares entitled to vote, were represented in person or by valid proxies. A description of each matter voted upon at the Annual Meeting is described in detail in GenMark’s definitive proxy statement filed with the Securities and Exchange Commission on April 13, 2018. Set forth below are final voting results for the four proposals that were subject to a vote of GenMark’s stockholders at the Annual Meeting.
|
1. |
For the proposal to elect two nominees for director to serve a three-year term expiring at GenMark’s 2021 Annual Meeting of Stockholders, the voting results were as follows: |
|
Name of Directors Elected |
For |
Withhold |
Broker Non-Votes |
|
Hany Massarany |
40,973,338 |
3,068,822 |
7,517,545 |
|
Kevin C. O’Boyle |
39,140,619 |
4,901,541 |
7,517,545 |
The following individuals are continuing directors with terms expiring at GenMark’s 2019 Annual Meeting of Stockholders: Lisa M. Giles and Michael S. Kagnoff.
The following individuals are continuing directors with terms expiring at GenMark’s 2020 Annual Meeting of Stockholders: Daryl J. Faulkner and James Fox, Ph.D.
|
2. |
For the proposal to approve the GenMark Amended and Restated 2013 Employee Stock Purchase Plan, the voting results were as follows: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|
43,987,418 |
46,257 |
8,485 |
7,517,545 |
|
3. |
For the proposal to ratify Ernst & Young LLP as GenMark’s independent registered public accounting firm for the fiscal year ending December 31, 2018, the voting results were as follows: |
|
For |
Against |
Abstain |
|
51,421,383 |
115,205 |
23,117 |
|
4. |
For the proposal to approve, on an advisory basis, the compensation of GenMark’s named executive officers, the voting results were as follows: |
|
For |
Against |
Abstain |
Broker Non-Votes |
|
12,552,136 |
31,340,884 |
149,140 |
7,517,545 |
No other matters were presented for stockholder approval at the Annual Meeting.
About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.
